List of Tables
    Table 1. Granulomatosis with Polyangiitis Drug CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Granulomatosis with Polyangiitis Drug Market Trends
    Table 3. Granulomatosis with Polyangiitis Drug Market Drivers
    Table 4. Granulomatosis with Polyangiitis Drug Market Challenges
    Table 5. Granulomatosis with Polyangiitis Drug Market Restraints
    Table 6. Global Granulomatosis with Polyangiitis Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Granulomatosis with Polyangiitis Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Granulomatosis with Polyangiitis Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Granulomatosis with Polyangiitis Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Granulomatosis with Polyangiitis Drug Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Granulomatosis with Polyangiitis Drug Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Granulomatosis with Polyangiitis Drug Sales Share by Manufacturer, 2017-2022
    Table 15. Global Granulomatosis with Polyangiitis Drug Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Granulomatosis with Polyangiitis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2021)
    Table 18. Top Players of Granulomatosis with Polyangiitis Drug in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Granulomatosis with Polyangiitis Drug Product Type
    Table 20. Date of International Manufacturers Enter into Granulomatosis with Polyangiitis Drug Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Granulomatosis with Polyangiitis Drug Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Granulomatosis with Polyangiitis Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Granulomatosis with Polyangiitis Drug Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Granulomatosis with Polyangiitis Drug Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Granulomatosis with Polyangiitis Drug Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Granulomatosis with Polyangiitis Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Granulomatosis with Polyangiitis Drug Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Granulomatosis with Polyangiitis Drug Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Granulomatosis with Polyangiitis Drug Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Granulomatosis with Polyangiitis Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Granulomatosis with Polyangiitis Drug Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Granulomatosis with Polyangiitis Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Granulomatosis with Polyangiitis Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Bionovis SA Corporation Information
    Table 43. Bionovis SA Description and Business Overview
    Table 44. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. Bionovis SA Granulomatosis with Polyangiitis Drug Product
    Table 46. Bionovis SA Recent Development
    Table 47. Bristol-Myers Squibb Company Corporation Information
    Table 48. Bristol-Myers Squibb Company Description and Business Overview
    Table 49. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 50. Bristol-Myers Squibb Company Product
    Table 51. Bristol-Myers Squibb Company Recent Development
    Table 52. ChemoCentryx Inc Corporation Information
    Table 53. ChemoCentryx Inc Description and Business Overview
    Table 54. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 55. ChemoCentryx Inc Product
    Table 56. ChemoCentryx Inc Recent Development
    Table 57. Coherus BioSciences Inc Corporation Information
    Table 58. Coherus BioSciences Inc Description and Business Overview
    Table 59. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 60. Coherus BioSciences Inc Product
    Table 61. Coherus BioSciences Inc Recent Development
    Table 62. Genor BioPharma Co Ltd Corporation Information
    Table 63. Genor BioPharma Co Ltd Description and Business Overview
    Table 64. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 65. Genor BioPharma Co Ltd Product
    Table 66. Genor BioPharma Co Ltd Recent Development
    Table 67. GlaxoSmithKline Plc Corporation Information
    Table 68. GlaxoSmithKline Plc Description and Business Overview
    Table 69. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 70. GlaxoSmithKline Plc Product
    Table 71. GlaxoSmithKline Plc Recent Development
    Table 72. Iltoo Pharma Corporation Information
    Table 73. Iltoo Pharma Description and Business Overview
    Table 74. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 75. Iltoo Pharma Product
    Table 76. Iltoo Pharma Recent Development
    Table 77. Panacea Biotec Ltd Corporation Information
    Table 78. Panacea Biotec Ltd Description and Business Overview
    Table 79. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 80. Panacea Biotec Ltd Product
    Table 81. Panacea Biotec Ltd Recent Development
    Table 82. Sandoz International GmbH Corporation Information
    Table 83. Sandoz International GmbH Description and Business Overview
    Table 84. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 85. Sandoz International GmbH Product
    Table 86. Sandoz International GmbH Recent Development
    Table 87. The International Biotechnology Center (IBC) Generium Corporation Information
    Table 88. The International Biotechnology Center (IBC) Generium Description and Business Overview
    Table 89. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 90. The International Biotechnology Center (IBC) Generium Product
    Table 91. The International Biotechnology Center (IBC) Generium Recent Development
    Table 92. Key Raw Materials Lists
    Table 93. Raw Materials Key Suppliers Lists
    Table 94. Granulomatosis with Polyangiitis Drug Customers List
    Table 95. Granulomatosis with Polyangiitis Drug Distributors List
    Table 96. Research Programs/Design for This Report
    Table 97. Key Data Information from Secondary Sources
    Table 98. Key Data Information from Primary Sources
List of Figures
    Figure 1. Granulomatosis with Polyangiitis Drug Product Picture
    Figure 2. Global Granulomatosis with Polyangiitis Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Granulomatosis with Polyangiitis Drug Market Size 2017-2028 (US$ Million)
    Figure 4. Global Granulomatosis with Polyangiitis Drug Sales 2017-2028 (K Pcs)
    Figure 5. United States Granulomatosis with Polyangiitis Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Granulomatosis with Polyangiitis Drug Market Size 2017-2028 (US$ Million)
    Figure 7. United States Granulomatosis with Polyangiitis Drug Sales 2017-2028 (K Pcs)
    Figure 8. United States Granulomatosis with Polyangiitis Drug Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Granulomatosis with Polyangiitis Drug Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Granulomatosis with Polyangiitis Drug Report Years Considered
    Figure 11. Product Picture of Benralizumab
    Figure 12. Product Picture of Avacopan
    Figure 13. Product Picture of Rituximab Biosimilar
    Figure 14. Product Picture of Others
    Figure 15. Global Granulomatosis with Polyangiitis Drug Market Share by Type in 2022 & 2028
    Figure 16. Global Granulomatosis with Polyangiitis Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 17. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type (2017-2028)
    Figure 18. Global Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028) & (K Pcs)
    Figure 19. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 20. Global Granulomatosis with Polyangiitis Drug Price by Type (2017-2028) & (USD/Pcs)
    Figure 21. United States Granulomatosis with Polyangiitis Drug Market Share by Type in 2022 & 2028
    Figure 22. United States Granulomatosis with Polyangiitis Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 23. United States Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type (2017-2028)
    Figure 24. United States Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028) & (K Pcs)
    Figure 25. United States Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 26. United States Granulomatosis with Polyangiitis Drug Price by Type (2017-2028) & (USD/Pcs)
    Figure 27. Product Picture of Hospital
    Figure 28. Product Picture of Clinic
    Figure 29. Product Picture of Others
    Figure 30. Global Granulomatosis with Polyangiitis Drug Market Share by Application in 2022 & 2028
    Figure 31. Global Granulomatosis with Polyangiitis Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 32. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application (2017-2028)
    Figure 33. Global Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028) & (K Pcs)
    Figure 34. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 35. Global Granulomatosis with Polyangiitis Drug Price by Application (2017-2028) & (USD/Pcs)
    Figure 36. United States Granulomatosis with Polyangiitis Drug Market Share by Application in 2022 & 2028
    Figure 37. United States Granulomatosis with Polyangiitis Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 38. United States Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application (2017-2028)
    Figure 39. United States Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028) & (K Pcs)
    Figure 40. United States Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 41. United States Granulomatosis with Polyangiitis Drug Price by Application (2017-2028) & (USD/Pcs)
    Figure 42. North America Granulomatosis with Polyangiitis Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 43. North America Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 44. U.S. Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Canada Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Europe Granulomatosis with Polyangiitis Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 47. Europe Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 48. Germany Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. France Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. U.K. Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Italy Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Russia Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 54. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 55. China Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Japan Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. South Korea Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. India Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Australia Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Taiwan Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Indonesia Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Thailand Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Malaysia Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Philippines Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Latin America Granulomatosis with Polyangiitis Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 66. Latin America Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 67. Mexico Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Brazil Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Argentina Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 71. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 72. Turkey Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Saudi Arabia Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. U.A.E Granulomatosis with Polyangiitis Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Granulomatosis with Polyangiitis Drug Value Chain
    Figure 76. Granulomatosis with Polyangiitis Drug Production Process
    Figure 77. Channels of Distribution
    Figure 78. Distributors Profiles
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed